{"id":2673,"date":"2020-05-29T18:24:24","date_gmt":"2020-05-29T18:24:24","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=2673"},"modified":"2020-07-08T07:44:35","modified_gmt":"2020-07-08T07:44:35","slug":"methods-of-treating-cells-containing-fusion-genes-2","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/methods-of-treating-cells-containing-fusion-genes-2\/","title":{"rendered":"Methods Of Treating Cells Containing Fusion Genes"},"content":{"rendered":"

Methods Of Treating Cells Containing Fusion Genes<\/h2>\n<\/div>
<\/div><\/div><\/div>

Inventors:<\/strong> Jianhua Luo: Yanping Yu: Zhanghui Chen: George Michalopoulos M.D., Ph.D.: Joel B. Nelson<\/p>\n

Patent Number:<\/strong> 15\/406,472<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and\/or prostate cancer-specific death after radical prostatectomy (each examples of \u201cprogressive prostate cancer\u201d), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>